Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Genfit is actively managing a portfolio in the Biotechnology & Pharmaceuticals technology area, which currently includes 3 pending office actions. This level of activity suggests a pipeline of pharmaceutical or biological innovations undergoing review. The prosecution is distributed across 3 distinct examiners, indicating that the company's applications are being evaluated by several different individuals at the patent office.
Furthermore, these cases are spread across 3 distinct art units. This distribution shows that Genfit's intellectual property spans multiple specialized sub-fields within the broader Biotechnology & Pharmaceuticals sector. For the company, this means that prosecution strategies must be tailored to the specific requirements and standards of 3 different administrative groups.
NEWTON, CHAD A is currently the busiest examiner for Genfit, with 1 pending office action under their review. Although this examiner is the busiest, they only handle 1 of the 3 pending office actions, which suggests a balanced distribution of work across the 3 distinct examiners. Practitioners should monitor the progress of the 3 pending office actions to identify any common themes or challenges that may arise across the different art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (75%) |
| §102 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEWTON, CHAD A | 1 | 38.4% | +23.4% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| ELKINS, BLAKE HARRISON | 1 | 100.0% | +0.0% |
| SABOUR, GHAZAL | 1 | 34.2% | +35.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569619 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | NEWTON, CHAD A | 43d overdue |
| 18378471 | SYSTEMS AND METHODS FOR PATIENT CLASSIFICATION | ELKINS, BLAKE HARRISON | — |
| 18250990 | METHODS OF DIAGNOSTIC OF LIVER FIBROSIS | SABOUR, GHAZAL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569619 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | NEWTON, CHAD A | 43d overdue |
| 18289511 | NITAZOXANIDE IN THE TREATMENT OF SEPSIS | FETTEROLF, BRANDON J | 4d overdue |
| 18250990 | METHODS OF DIAGNOSTIC OF LIVER FIBROSIS | SABOUR, GHAZAL | — |
| Art Unit | Apps |
|---|---|
| 3681 | 1 |
| 1626 | 1 |
| 1687 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569619 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | NEWTON, CHAD A | 3681 | §101§103§112 | Non-Final OA | 43d overdue | Pending | Dec 13, 2023 |
| 18289511 | NITAZOXANIDE IN THE TREATMENT OF SEPSIS | FETTEROLF, BRANDON J | 1626 | §102 | Non-Final OA | 4d overdue | Pending | Nov 03, 2023 |
| 18378471 | SYSTEMS AND METHODS FOR PATIENT CLASSIFICATION | ELKINS, BLAKE HARRISON | 1687 | §101§103§112 | Non-Final OA | — | Pending | Oct 10, 2023 |
| 18250990 | METHODS OF DIAGNOSTIC OF LIVER FIBROSIS | SABOUR, GHAZAL | 1686 | §101§103§112DP | Non-Final OA | — | Pending | Apr 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenfit has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Chad A Newton has the most, with 1 of Genfit's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
